Umbilical Cord Allogeneic Cells With Low Immune Rejection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Clinical translation of various cell types for human and animal therapeutic applications is limited due to allogenic issues, including immune recognition and compatibility.

Innovation Solution

Isolation and culture of cells from the subepithelial layer of mammalian umbilical cord tissue, which express specific markers and lack others, allowing for self-renewal and differentiation into multiple cell types, and can be administered without causing a mixed lymphocyte response, using media free of animal products and enzymes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If allogenic cells are used for therapeutic applications, then cell availability and productivity are improved, but immune recognition and rejection occur

Engineering Contradiction:

Improvecell availabilityVSAvoidimmune rejection

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the immunological parameters of the cells by isolating them from a specific tissue source (subepithelial layer of umbilical cord) and culturing them under defined conditions. This results in cells with altered surface marker expression profiles that reduce immunogenicity while maintaining therapeutic functionality, thereby resolving the contradiction between cell availability and immune rejection

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a standardized cell product from umbilical cord tissue that can be manufactured consistently without requiring immunematching between donor and recipient. The cells are cultured to expansion and can be administered allogeneically without causing mixed lymphocyte response, effectively copying the desired therapeutic effect while avoiding immune compatibility issues

Inventive Principle:

Principle #26Copying

2Adaptability or versatility

If cells are isolated from subepithelial layer of umbilical cord, then self-renewal and differentiation capacity are improved, but isolation complexity increases

Engineering Contradiction:

Improvedifferentiation capacityVSAvoidisolation complexity

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent extracts the subepithelial layer from the umbilical cord tissue, separating it from other tissue components. This targeted extraction of the specific layer containing the desired stem cells simplifies the isolation process by focusing on a defined anatomical structure with known cellular composition, thereby reducing overall isolation complexity while maintaining high differentiation capacity

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent segments the umbilical cord tissue into distinct layers, specifically isolating the subepithelial layer. This segmentation approach allows for targeted harvesting of stem cells from the appropriate tissue compartment, improving cell quality and multipotency while streamlining the isolation procedure through systematic tissue dissection

Inventive Principle:

Principle #1Segmentation

Data Source

PatentUS20260078347A1Clinical derivations of an allogenic cell and therapeutic uses

Publication Date: 2026.03.19 JADI CELL LLC

AI summary

Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.